PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 296.7K (Avg.)
-1.36 | -1.31
Steady, sustainable growth is a hallmark of high-quality businesses. Value investors watch these metrics to confirm that the company's fundamental performance aligns with—or outpaces—its current market valuation.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
121.05%
Positive EBIT growth while AVXL is negative. John Neff might see a substantial edge in operational management.
-6.92%
Both companies face negative operating income growth. Martin Whitman would suspect broader market or cost hurdles.
121.05%
Positive net income growth while AVXL is negative. John Neff might see a big relative performance advantage.
121.15%
Positive EPS growth while AVXL is negative. John Neff might see a significant comparative advantage in per-share earnings dynamics.
115.11%
Positive diluted EPS growth while AVXL is negative. John Neff might view this as a strong relative advantage in controlling dilution.
2.25%
Share count expansion well above AVXL's 1.06%. Michael Burry would question if management is raising capital unnecessarily or is over-incentivizing employees with stock.
42.15%
Slight or no buyback while AVXL is reducing diluted shares. John Neff might consider the competitor’s approach more shareholder-friendly.
No Data
No Data available this quarter, please select a different quarter.
-3.22%
Negative OCF growth while AVXL is at 20.11%. Joel Greenblatt would demand a turnaround plan focusing on real cash generation.
-8.23%
Negative FCF growth while AVXL is at 20.53%. Joel Greenblatt would demand improved cost control or more strategic capex discipline.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-39049.73%
Both show negative 10Y OCF/share CAGR. Martin Whitman would question if the entire market or product set is shrinking or too capital-intensive.
-717224.10%
Negative 5Y OCF/share CAGR while AVXL is at 50.84%. Joel Greenblatt would question the firm’s operational model or cost structure.
-12351.82%
Negative 3Y OCF/share CAGR while AVXL stands at 60.80%. Joel Greenblatt would demand an urgent turnaround in the firm’s cost or revenue drivers.
45138.86%
Positive 10Y CAGR while AVXL is negative. John Neff might see a substantial advantage in bottom-line trajectory.
41496.01%
5Y net income/share CAGR above 1.5x AVXL's 56.62%. David Dodd would confirm if the firm’s strategy is more effective in generating mid-term profits.
7331.25%
3Y net income/share CAGR above 1.5x AVXL's 65.68%. David Dodd would confirm the company’s short-term strategies outmatch the competitor significantly.
8529.17%
Equity/share CAGR of 8529.17% while AVXL is zero. Bruce Berkowitz might see a slight advantage that can compound significantly over 10 years.
2357.47%
5Y equity/share CAGR above 1.5x AVXL's 239.15%. David Dodd might see stronger earnings retention or fewer asset impairments fueling growth.
2495.43%
3Y equity/share CAGR above 1.5x AVXL's 554.61%. David Dodd verifies the company’s short-term capital management far exceeds the competitor’s pace.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
135.47%
Asset growth well under 50% of AVXL's 6721.34%. Michael Burry sees the competitor as far more aggressive in building resources or capacity.
131.44%
Under 50% of AVXL's 598.14%. Michael Burry raises concerns about the firm’s ability to build intrinsic value relative to its rival.
-41.82%
Both reduce debt yoy. Martin Whitman sees a broader sector shift to safer balance sheets or less growth impetus.
-18.65%
Our R&D shrinks while AVXL invests at 2180.93%. Joel Greenblatt checks if we risk falling behind a competitor’s new product pipeline.
44.07%
SG&A declining or stable vs. AVXL's 197.50%. David Dodd sees better overhead efficiency if it doesn't hamper revenue.